Table 1 Characteristics of ART naïve study participants, February–September 2013, Addis Ababa, Ethiopia
Variables | Number | % (CI 95%) |
|---|---|---|
Gender | ||
Male | 171 | 28.8 (22.0–35.6) |
Female | 423 | 71.2 (66.9–75.5) |
Marital status | ||
Never married | 109 | 18.4 (11.1–25.7) |
Married/living with partner | 293 | 49.3 (43.6–55.0) |
Divorced/widowed/separated | 192 | 32.3 (25.7–38.9) |
BMI (kg/m2) | ||
< 18.5 | 87 | 15.1 (7.6–22.6) |
18.5–24.9 | 362 | 62.8 (57.8–67.8) |
25.0–29.9 | 96 | 16.7 (9.2–24.2) |
≥ 30 | 31 | 5.4 (−2.6–13.4) |
Length of time stay positive (years) | ||
< 1 | 150 | 26.1 (19.1–33.1) |
1–3 | 177 | 30.8 (23.8–37.4) |
> 3 | 248 | 43.1 (37.1–49.5) |
WHO clinical stage | ||
Stage 1 | 328 | 55.6 (50.2–61.0) |
Stage 2 | 177 | 30.0 (23.2–36.8) |
Stage ¾ | 85 | 14.4 (6.9–21.9) |
CD4+ T cell count (cells/mm3) | ||
< 200 | 102 | 17.2 (9.9–24.5) |
200–349 | 182 | 30.6 (23.8–37.3) |
350–499 | 144 | 24.2 (17.2–31.2) |
≥ 500 | 166 | 28.0 (21.2–34.8) |
Hemoglobin level (g/dl) | ||
Non-anemic | 507 | 88.8 (86.1–91.5) |
Anemic | 64 | 11.2 (3.5–18.9) |
Cholesterol level (mg/dl) | ||
≤ 200 | 472 | 83.3 (79.9–86.7) |
> 200 | 95 | 16.7 (9.2–24.2) |
HIV RNA load (copies/mL) | ||
< 10,000 | 427 | 45.2(39.2–51.2) |
≥ 10,000 | 157 | 54.8(49.3–60.3) |
HIV RNA load in log copies/mL (mean ± standard deviation) | 500 | 4.23 ± 0.83 |